Caris Life Sciences released interim Achieve 1 validation data for its Caris Detect multicancer early detection (MCED) assay showing stage‑dependent sensitivity and high specificity. The diagnosed cohort showed sensitivity rising with stage—roughly 57% for stage I, 70% for stage II, 77% for stage III and 99% for stage IV—while specificity in undiagnosed participants was about 95%. Caris said an independent blinded validation cohort remains withheld for follow‑up testing. The company plans a Q2 launch pending validation and regulatory steps. Payers, clinicians and screening‑program operators will scrutinize prospective performance, false‑positive rates, and clinical pathways for positive findings.